IOVA · Iovance Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.43M | - | $67.45M | $59.95M | $49.32M | - | $58.55M | $31.11M | $715.0K | - |
| Cost of Revenue | $42.50M | - | $38.48M | $56.66M | $49.74M | - | $39.82M | $31.37M | $7.26M | - |
| Gross Profit | $28.93M | - | $28.98M | $3.29M | ($417.0K) | - | $18.73M | ($262.0K) | ($6.55M) | - |
| R&D | $62.49M | - | $75.17M | $79.36M | $76.88M | - | $68.25M | $62.08M | $79.78M | - |
| SG&A | $38.95M | - | $34.55M | $37.70M | $43.92M | - | $39.55M | $39.57M | $31.39M | - |
| Total Operating Expenses | $152.47M | - | $162.36M | $173.73M | $170.54M | - | $147.62M | $133.02M | $118.44M | - |
| D&A | $2.82M | - | $9.01M | $3.40M | $2.79M | - | $3.00M | $3.00M | $2.98M | - |
| Operating Income | ($81.04M) | - | ($94.90M) | ($113.77M) | ($121.22M) | - | ($89.07M) | ($101.91M) | ($117.72M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($665.0K) | - | ($2.40M) | $1.99M | ($1.84M) | - | ($1.52M) | ($1.46M) | ($1.41M) | - |
| Net Income | ($79.05M) | - | ($91.25M) | ($111.66M) | ($116.16M) | - | ($83.54M) | ($97.10M) | ($112.98M) | - |
| EPS - Basic | ($0.19) | - | ($0.25) | ($0.33) | ($0.36) | - | ($0.28) | ($0.34) | ($0.42) | - |
| EPS - Diluted | ($0.19) | - | - | ($0.33) | ($0.36) | - | ($0.28) | ($0.34) | ($0.42) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $196.51M | $163.08M | $158.13M | $132.47M | $171.67M | $115.69M | $164.19M | $228.68M | $134.19M | $114.89M |
| Accounts Receivable | $81.76M | $82.45M | $66.76M | $59.94M | $70.94M | $69.34M | $55.77M | $31.60M | $234.0K | $151.0K |
| Inventory | $58.38M | $51.68M | $51.71M | $49.83M | $65.55M | $51.52M | $38.58M | $27.85M | $17.62M | $10.37M |
| Accounts Payable | $37.45M | $22.16M | $31.24M | $32.00M | $28.49M | $27.51M | $31.69M | $20.42M | $25.70M | $33.12M |
| Current Assets | $466.50M | $442.69M | $429.09M | $422.50M | $512.65M | $457.02M | $498.58M | $482.26M | $385.53M | $307.85M |
| Total Assets | $925.66M | $913.17M | $904.95M | $907.44M | $966.74M | $910.43M | $991.12M | $964.32M | $869.83M | $780.35M |
| Current Liabilities | $129.42M | $138.36M | $125.78M | $129.16M | $122.69M | $122.34M | $118.06M | $93.64M | $83.21M | $110.31M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $203.91M | $214.59M | $202.66M | $208.95M | $198.88M | $200.02M | $217.66M | $195.78M | $189.81M | $195.74M |
| Stockholders' Equity | $721.75M | $698.58M | $702.29M | $698.49M | $767.87M | $710.40M | $773.46M | $768.54M | $680.02M | $584.61M |
| Retained Earnings | ($2.85B) | ($2.78B) | ($2.70B) | ($2.61B) | ($2.50B) | ($2.38B) | ($2.31B) | ($2.22B) | ($2.13B) | ($2.01B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($72.07M) | - | - | - | ($103.69M) | - | - | - | ($122.28M) | - |
| Investing Cash Flow | $11.39M | - | - | - | $15.87M | - | - | - | ($111.51M) | - |
| Financing Cash Flow | $94.33M | - | - | - | $143.31M | - | - | - | $193.58M | - |
| CapEx | $6.61M | - | - | - | $6.21M | - | - | - | $4.17M | - |
| Free Cash Flow | ($78.68M) | - | - | - | ($109.91M) | - | - | - | ($126.45M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 40.5% | - | 43.0% | 5.5% | -0.8% | - | 32.0% | -0.8% | -915.5% | - |
| Operating margin | -113.5% | - | -140.7% | -189.8% | -245.8% | - | -152.1% | -327.6% | -16464.6% | - |
| EBITDA margin | -109.5% | - | -127.3% | -184.1% | -240.1% | - | -147.0% | -318.0% | -16048.1% | - |
| Net margin | -110.7% | - | -135.3% | -186.2% | -235.5% | - | -142.7% | -312.2% | -15800.8% | - |
| Free cash flow margin | -110.2% | - | - | - | -222.8% | - | - | - | -17685.3% | - |
| FCF / Net income | 1.00 | - | - | - | 0.95 | - | - | - | 1.12 | - |
| R&D / Revenue | 87.5% | - | 111.4% | 132.4% | 155.9% | - | 116.5% | 199.6% | 11158.5% | - |
| SG&A / Revenue | 54.5% | - | 51.2% | 62.9% | 89.1% | - | 67.5% | 127.2% | 4390.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.5% | - | -10.1% | -12.3% | -12.0% | - | -8.4% | -10.1% | -13.0% | - |
| Return on equity | -11.0% | - | -13.0% | -16.0% | -15.1% | - | -10.8% | -12.6% | -16.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.60 | 3.20 | 3.41 | 3.27 | 4.18 | 3.74 | 4.22 | 5.15 | 4.63 | 2.79 |
| Quick ratio | 3.15 | 2.83 | 3.00 | 2.89 | 3.64 | 3.31 | 3.90 | 4.85 | 4.42 | 2.70 |
| Cash ratio | 1.52 | 1.18 | 1.26 | 1.03 | 1.40 | 0.95 | 1.39 | 2.44 | 1.61 | 1.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.31 | 1.29 | 1.30 | 1.26 | 1.28 | 1.28 | 1.25 | 1.28 | 1.33 |
| Liabilities / Assets | 0.22 | 0.23 | 0.22 | 0.23 | 0.21 | 0.22 | 0.22 | 0.20 | 0.22 | 0.25 |
| Efficiency | ||||||||||
| Asset turnover | 0.08 | - | 0.07 | 0.07 | 0.05 | - | 0.06 | 0.03 | 0.00 | - |
| Inventory turnover | 0.73 | - | 0.74 | 1.14 | 0.76 | - | 1.03 | 1.13 | 0.41 | - |
| Days sales outstanding | 418d | - | 361d | 365d | 525d | - | 348d | 371d | 119d | - |
| Days inventory outstanding | 501d | - | 491d | 321d | 481d | - | 354d | 324d | 886d | - |
| Days payable outstanding | 322d | - | 296d | 206d | 209d | - | 290d | 238d | 1292d | - |
| Cash conversion cycle | 598d | - | 555d | 480d | 797d | - | 411d | 457d | -287d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.0x | - | - | 0.0x | 0.0x | - | 0.0x | 0.0x | 5.8x | - |
| P / S | 0.0x | - | - | 0.0x | 0.0x | - | 0.0x | 0.1x | 5518.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 44.8% | - | 15.2% | 92.7% | 6798.5% | - | 12385.1% | 12969.7% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | 54.7% | - | 93.6% | - | - | 85.5% | - | - |
| Operating income growth (YoY) | 33.1% | - | -6.6% | -11.6% | -3.0% | - | 24.8% | 7.4% | -6.2% | - |
| Net income growth (YoY) | 32.0% | - | -9.2% | -15.0% | -2.8% | - | 26.6% | 8.8% | -5.2% | - |
| EPS growth (YoY) | 47.2% | - | - | 2.9% | 14.3% | - | 39.1% | 27.7% | 16.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 28.4% | - | - | - | 13.1% | - | - | - | -19.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.0% | -1.7% | -9.2% | -9.1% | 12.9% | 21.5% | 14.8% | 32.8% | 2.0% | 17.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$263.50M totalSingle Reportable Segment$263.50M · 100.0%
Product / service
$263.50M totalAmtagvi$220.02M · 83.5%
Proleukin$43.48M · 16.5%
Geographic
$263.50M totalUS$259.01M · 98.3%
Non Us$4.49M · 1.7%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing IOVANCE BIOTHERAPEUTICS against the 5 most active filers in the same SIC group.